A new case report was published in Oncoscience on September 20, 2023, entitled, “Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.”

Pazopanib, a multi-kinase VEGF inhibitor, is currently FDA approved for advanced renal cell carcinoma and advanced soft tissue sarcoma; but limited evidence exists on its efficacy in bone sarcomas.

In this case report, researchers Mohamed A. Gouda, Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang, and Vivek Subbiah from The University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumour control through using pazopanib and surgery for an overall duration exceeding 5 years.

The report also reviews the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.

Source: Impact Journals LLC